{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.1","value":"22.1"},{"groupId":"OG001","spread":"11.9","value":"31.7"}]}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.3","value":"20.3"},{"groupId":"OG001","spread":"34.7","value":"30.2"}]}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.3","value":"21.0"},{"groupId":"OG001","spread":"6.6","value":"29.2"}]}],"title":"Cycle 1 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.0","value":"20.9"},{"groupId":"OG001","spread":"16.2","value":"29.2"}]}],"title":"Cycle 1 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Tisotumab vedotin 0.9 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).","id":"OG000","title":"Part 1: Dose Escalation: Cohort 1 3q4wk 0.9mg/kg"},{"description":"Tisotumab vedotin 1.2 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).","id":"OG001","title":"Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Insufficient samples were taken in Cycle 2 and beyond to calculate PK parameters, therefore only Cycle 1 is reported. Cycle 1 is an overall value, calculated over the entire cycle.","reportingStatus":"POSTED","timeFrame":"Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1","title":"Part 1: Cmax: Maximum Observed Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)","type":"SECONDARY","unitOfMeasure":"µg/mL"}